Pabau Engage inbox

Pabau Engage is here: every patient conversation in one inbox.

Learn more
Book a demo Book a demo
☰
HCPCS Code

HCPCS code J7518 – Oral mycophenolic acid, 180 mg


Code Definition

J7518 is the HCPCS Level II code for mycophenolic acid, oral, 180 mg. It covers Myfortic and generic delayed-release tablets, at one billing unit per 180 mg.

Medicare pays for it under the Part B immunosuppressive drug benefit, after a Medicare-covered organ transplant. Pharmacies bill the DME MAC with a transplant diagnosis such as Z94.0.

Level
Level II
Category
J — Drugs administered other than oral method
Status
Active
Billable
No
Code also known as
Myfortic, mycophenolic acid delayed-release 180 mg
Save time. Improve accuracy. Get paid faster.
Automate coding with Pabau

Let Pabau's smart automation suggest the right codes, reduce claim denials, and keep your practice compliant—effortlessly.

  • AI-powered code suggestions
  • Real-time compliance checks
  • Faster claims, fewer denials
Why practices choose Pabau
Save hours every week

Automate repetitive tasks and focus on what matters most—your patients.

Improve accuracy

Reduce coding errors and ensure compliance with the latest regulations.

Get paid faster

Clean claims, fewer denials, and faster reimbursements.

Grow with confidence

Powerful insights and reporting to help your practice thrive.

HIPAA compliant SOC 2 certified GDPR-compliant Trusted by 4,000+ clinics worldwide

Key takeaways

Key takeaways

HCPCS code J7518 is mycophenolic acid, oral, 180 mg, covering Myfortic and generic delayed-release tablets.

One unit equals 180 mg, so a 180 mg tablet bills as 1 unit and a 360 mg tablet as 2 units.

Medicare Part B pays for J7518 only after a Medicare-covered organ transplant, through the DME MAC.

A transplant diagnosis such as Z94.0 or a T86.1- kidney transplant code supports medical necessity.

The Medicare payment limit is $0.257 per unit from October 1 to December 31, 2026.

J7518 was not touched by the October 2026 mycophenolate changes, but J7517 and J7519 were deleted.

HCPCS code J7518 covers oral mycophenolic acid, one unit per 180 mg

HCPCS code J7518 is the Level II code for mycophenolic acid, oral, 180 mg. The CMS Medicare Part B payment limit file lists it with a 180 mg billing unit. Medicare pays for it under the immunosuppressive drug benefit, after a Medicare-covered organ transplant.

The drug is sold as Myfortic, by Novartis, and as generic mycophenolic acid delayed-release tablets. Both strengths, 180 mg and 360 mg, bill under the same code.

FieldDetail
HCPCS codeJ7518
Official descriptorMycophenolic acid, oral, 180 mg
Billing unit1 unit = 180 mg
DrugMycophenolic acid, as mycophenolate sodium, delayed-release tablets
Brand and genericsMyfortic (Novartis) and generic mycophenolic acid DR tablets
Tablet strengths180 mg (1 unit) and 360 mg (2 units)
Code rangeJ7500-J7599, immunosuppressive drugs
Medicare benefitPart B immunosuppressive drug benefit, billed to the DME MAC
Payment limit, Q4 2026$0.257 per 180 mg unit, October 1 to December 31, 2026
Code statusActive. Not changed by the October 2026 HCPCS update

Drug overview: mycophenolic acid (Myfortic)

Mycophenolic acid is an antimetabolite immunosuppressant. It blocks the purine synthesis that T and B lymphocytes rely on, which dampens the immune response that drives organ rejection.

The Myfortic prescribing information on DailyMed approves it for prophylaxis of organ rejection after a kidney transplant. It is given with cyclosporine and corticosteroids. The usual adult dose is 720 mg twice a day.

Myfortic is an enteric-coated, delayed-release tablet, and patients swallow it whole. It is not interchangeable milligram for milligram with mycophenolate mofetil, the drug in CellCept. That difference is why the two drugs never share a HCPCS code.

Medicare Part B coverage for J7518

Medicare Part B covers J7518 under the immunosuppressive drug benefit. The DME MAC policy article Immunosuppressive Drugs (A52474) sets the criteria, and a claim has to meet all of them.

  • A qualifying transplant: kidney, heart, liver, lung, heart-lung, intestinal, bone marrow or stem cell, or a specified pancreas or islet transplant.
  • Medicare at the right times: the patient had Part A when the transplant happened and has Part B on the date the drug is dispensed.
  • A transplant-related use: the drug prevents or treats rejection. Use for a non-transplant diagnosis is denied.
  • A pharmacy or supplier claim: the dispensing supplier bills the DME MAC, not the Part B MAC that pays physicians.

Kidney recipients whose Medicare is based on end-stage renal disease alone lose it 36 months after a successful transplant. Since January 1, 2023, they can enroll in the Part B immunosuppressive drug benefit (Part B-ID). It covers these drugs only, with the Part B deductible and 20% coinsurance.

Part D steps in when Part B does not apply. A patient whose transplant Medicare did not cover usually fills mycophenolic acid through a Part D plan. The same goes for off-label use outside transplant care.

How to count J7518 units

Divide the total milligrams dispensed by 180. Mycophenolic acid tablets only come in 180 mg and 360 mg strengths, so the result is always a whole number.

DispensedTotal mgJ7518 units
One 180 mg tablet180 mg1
One 360 mg tablet360 mg2
720 mg twice daily, 1 day1,440 mg8
720 mg twice daily, 30 days43,200 mg240
720 mg twice daily, 90 days129,600 mg720
Bottle of 120 × 360 mg tablets43,200 mg240

Count milligrams, not tablets. A pharmacy that bills one unit per tablet underbills every 360 mg tablet by half.

J7518 payment limit and reimbursement in 2026

Medicare pays J7518 from the Average Sales Price methodology, at the limit in the quarterly CMS ASP pricing files. The physician fee schedule does not price it, so skip that lookup.

QuarterPayment limit per 180 mg unitCoinsurance
July 1 to September 30, 2026$0.32520%
October 1 to December 31, 2026$0.25720%

Take a 30-day supply at 720 mg twice daily, or 240 units. At the October 2026 limit, the allowed amount is 240 × $0.257, or $61.68. Medicare pays 80%, $49.34, once the Part B deductible is met, and the patient owes $12.34.

Flow showing a 30-day J7518 claim
A 30-day fill at the usual adult dose comes to 240 units and $61.68 allowed, and counting tablets instead halves the units. Figures from the CMS ASP payment limit file for October to December 2026.

The limit moves every quarter. Check the file for the quarter the date of service falls in before you quote a patient a figure.

ICD-10 codes that support a J7518 claim

A transplant diagnosis carries medical necessity. Policy article A52474 lists the Z94 transplant status codes, the T86 transplant complication codes, and Z48.2- aftercare codes. These are the pairings that come up most with mycophenolic acid.

ICD-10-CM codeDescriptionWhen it fits
Z94.0Kidney transplant statusRoutine maintenance therapy after a kidney transplant
T86.11Kidney transplant rejectionThe drug is part of treating an active rejection episode
T86.12Kidney transplant failureGraft failure documented while therapy continues
T86.19Other complication of kidney transplantA documented complication with no more specific code
Z48.22Encounter for aftercare following kidney transplantAftercare encounters in the early post-transplant period
Z94.4Liver transplant statusLiver recipients, where the use is off-label but transplant-related

Listing a code does not guarantee payment on its own. The record still needs the transplant date, the transplant type, and the prescriber’s order. For a rejection episode, T86.11 is the code to pair with the claim, and the notes should show how the rejection was diagnosed.

NDC crosswalk for J7518

The October 2026 ASP NDC-HCPCS crosswalk, published with the CMS ASP pricing files, maps Myfortic and the generics to J7518. A few of the listed products are below.

NDCProductStrength and packBilling units per pack
00078-0385-66Myfortic DR (Novartis)180 mg, 120 tablets120
00078-0386-66Myfortic DR (Novartis)360 mg, 120 tablets240
16729-0261-29Mycophenolic acid DR (Accord)180 mg, 120 tablets120
60505-2966-07Mycophenolic acid DR (Apotex)360 mg, 120 tablets240
59651-0622-08Mycophenolic acid DR (Aurobindo)360 mg, 120 tablets240

Report the NDC in the 11-digit 5-4-2 format with the N4 qualifier when the payer asks for it. Medicaid and commercial plans usually do, so confirm the rule with each one.

Modifiers and supply fees billed with J7518

Pharmacies billing the DME MAC add a modifier that says whether the coverage criteria are met. They also bill a supply fee on the same claim as the drug.

CodeWhat it meansWhen to use it
KXCoverage criteria in A52474 are metThe transplant date is on file and comes before the date of service
GYItem does not meet a Medicare benefitAny of the A52474 criteria is not met
Q0510Supply fee, first month after transplantOne unit, on the first claim after the transplant, in place of Q0511 or Q0512
Q0511Supply fee, first drug in the periodOne unit for the first covered drug per 30- or 90-day period
Q0512Supply fee, each additional drugOne unit for each further covered drug in the same period

Pro Tip

Record the transplant date in the patient record before the first fill. KX depends on it, and a missing date turns a clean claim into a GY denial.

Don’t mix up J7518 with the mycophenolate mofetil codes

Mycophenolic acid and mycophenolate mofetil are different drugs with different codes. The October 2026 HCPCS update made this harder, because it deleted two mofetil codes, J7517 and J7519. Check the CMS HCPCS quarterly update before you reuse an old claim template.

CodeDescriptorStatus
J7518Mycophenolic acid, oral, 180 mgActive
J7517Mycophenolate mofetil, oral, 250 mgDeleted for dates of service from October 1, 2026
J7524Mycophenolate mofetil, oral, 5 mgNew October 1, 2026, replacing J7517
J7519Injection, mycophenolate mofetil, 10 mgDeleted for dates of service from October 1, 2026
J7526Injection, mycophenolate mofetil, 5 mgNew October 1, 2026, replacing J7519
J7515Cyclosporine, oral, 25 mgActive, a different immunosuppressant

Myfortic always bills as J7518. CellCept and generic mycophenolate mofetil bill as J7524 from October 1, 2026, at 5 mg per unit. The unit sizes alone make a swapped code obvious in a pre-bill review. Cyclosporine is a different drug again, billed as J7515 in 25 mg units.

Common J7518 billing errors

Most J7518 denials trace back to a handful of avoidable mistakes. Our denial code reference explains the reason codes that come back.

ErrorWhat goes wrongFix
Units counted per tabletEvery 360 mg tablet is billed as 1 unit instead of 2Divide total milligrams by 180
Myfortic billed as a mofetil codeThe NDC does not crosswalk to the code billedBill mycophenolic acid as J7518 only
Deleted code still in the templateJ7517 or J7519 on a date of service from October 1, 2026Switch to J7524 or J7526
No transplant diagnosisThe claim reads as a non-transplant useAdd Z94.0, a T86 code or a Z48.2- code
KX without a transplant dateThe criteria cannot be confirmedGet the transplant date on file first
Claim sent to the wrong contractorA pharmacy claim goes to the Part B MACSend it to the DME MAC
Supply fee on a separate claimQ0511 or Q0512 is not paidBill the supply fee with the drug

When a claim does deny, denial management starts with the remittance code. Fix the line it names and resubmit, rather than appealing a coding error.

How Pabau keeps transplant drug claims together

A J7518 claim leans on details that sit in different places: the transplant date, the prescription, and the diagnosis. When they live in separate systems, someone retypes them, and that is where KX and unit errors start.

Pabau, a practice management platform with built-in billing tools, keeps them on one patient record. Its claims management software submits the claim you build from that record and tracks what comes back.

Your team can see the transplant date, the prescription, and the claim status without switching screens. That makes it easier to catch a missing date before the claim goes out.

Keep transplant drug claims tied to the patient record

Pabau holds the transplant date, the prescription history, and the claim status on one patient record. Your billing team builds each J7518 claim from data already there.

Pabau claims management dashboard

Conclusion

J7518 is mycophenolic acid, and only mycophenolic acid. Once the drug is right, the claim turns on two facts: units in 180 mg steps, and a Medicare-covered transplant on file.

The October 2026 update moved the mofetil codes, not this one. Use it as the moment to clean out old templates, and the J7518 claims that follow will go out clean the first time.

Book a demo to see how Pabau keeps transplant drug claims tied to the patient record.

Continue your research

Continue your research

Billing another oral immunosuppressant? HCPCS code J7520 walks through oral sirolimus under the same Part B benefit.

Need a broader HCPCS reference? What is medical billing explains how J-code drug claims fit into the broader revenue cycle.

Struggling with claim denials across your practice? Denial management in healthcare covers the full appeal workflow from CARC code to corrected claim.

Want a clean claim checklist for drug billing? What is a clean claim outlines every field a payer checks before accepting a drug claim for processing.

Frequently asked questions

What drug does HCPCS code J7518 represent?

HCPCS code J7518 represents mycophenolic acid, oral, 180 mg. It covers Myfortic and generic mycophenolic acid delayed-release tablets. The drug prevents organ rejection after a kidney transplant.

What is the billing unit for J7518?

One unit of J7518 equals 180 mg. A 180 mg tablet bills as 1 unit and a 360 mg tablet as 2 units. A 30-day supply at 720 mg twice daily is 240 units.

Does Medicare Part B cover J7518?

Yes, after a Medicare-covered organ transplant. The patient needs Part A at the time of the transplant and Part B when the drug is dispensed. The pharmacy bills the DME MAC under policy article A52474.

What does Medicare pay for J7518 in 2026?

The Part B payment limit is $0.257 per 180 mg unit from October 1 to December 31, 2026. It was $0.325 from July 1 to September 30, 2026. Medicare pays 80% after the deductible.

Which ICD-10 codes support a J7518 claim?

Transplant codes support it. Z94.0 covers kidney transplant status, and T86.1- codes cover kidney transplant complications such as rejection. Z48.22 covers aftercare following a kidney transplant.

Is Myfortic billed with J7517 or J7519?

No. Myfortic is mycophenolic acid and always bills as J7518. J7517 and J7519 were mycophenolate mofetil codes, and both were deleted for dates of service from October 1, 2026.

Avatar photo
Despina Petrushevska
Content Writer

Despina Petrushevska is a content writer covering aesthetics, dermatology, and clinic operations, known for making detailed clinical concepts clear and engaging. Outside of work, she enjoys photography, weekend getaways, and finding inspiration in everyday experiences.
×